Last reviewed · How we verify
Starasid (cytarabine ocfosfate)
Starasid (generic name: cytarabine ocfosfate) is a Nucleoside Metabolic Inhibitor drug. It is currently in unknown development.
Starasid works by interfering with the replication of DNA in cancer cells, preventing them from growing and dividing.
Starasid (cytarabine ocfosfate) is a nucleoside metabolic inhibitor, a small molecule drug that targets cancer cells. It is used to treat certain types of cancer, but its exact target is unknown. The commercial status of Starasid is unclear, and it may be patented or have generic manufacturers. Key safety considerations include potential side effects, but specific details are not available. Further research is needed to fully understand the drug's properties and uses.
At a glance
| Generic name | cytarabine ocfosfate |
|---|---|
| Drug class | Nucleoside Metabolic Inhibitor |
| Therapeutic area | Oncology |
| Phase | unknown |
Mechanism of action
Imagine DNA as a blueprint for a house. Starasid is like a tool that prevents the blueprint from being copied, so the house can't be built. This stops the cancer cells from growing and dividing, which can help slow down or even stop the growth of the tumor.
Approved indications
Common side effects
Key clinical trials
- A Phase II Trial of Fludarabine in Combination With Daunorubicin and Cytarabine Liposome for Adults With Newly-diagnosed Acute Myeloid Leukemia: University of California Hematologic Malignancies Conso (Phase 2)
- A Phase I/II Trial of CLT-008 Myeloid Progenitor Cells in Patients Receiving Chemotherapy for Leukemia or Myelodysplasia (Phase 1)
- A Prospective, Multicenter, Single Arm Clinical Study to Evaluate Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia (Phase 2)
- Observational Prospective Study, Evaluating the Standard of Care as Recommend by International Consensus With Zidovudine-Pegylated Interferon +/-Polychemotherapy in High Risk Adult-T-cell Lymphoma/Leu (N/A)
- A Phase I Trial of BBR 2778 in Combination With Cytarabine, Methylprednisolone and Cisplatin in the Treatment of Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (Phase 1)
- Transplantation After Complete Response In Patients With T-cell Lymphoma (NA)
- Phase III Randomised Study on Liposomal Cytarabine (DepoCyte®) vs. Intrathecal Triple for CNS-Treatment During Maintenance Therapy in High-Risk Acute Lymphoblastic Leukemia Patients in NOPHO ALL 2008 (Phase 3)
- A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Starasid CI brief — competitive landscape report
- Starasid updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Starasid
What is Starasid?
How does Starasid work?
What is the generic name of Starasid?
What drug class is Starasid in?
What development phase is Starasid in?
Related
- Drug class: All Nucleoside Metabolic Inhibitor drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Oncology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing